Search Results

bioAffinity Technologies, Inc., a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, reported 139% growth in the number of pulmonology practices and physicians offering CyPath® Lung to patients since Jan. 1, 2024.

bioAffinity Technologies, Inc., a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, reported financial results for the three months ended March 31, 2024.

bioAffinity Technologies, Inc. today reported financial results for the three and 12 months ended December 31, 2023.

bioAffinity Technologies, Inc. provides a summary of recent Company news.

bioAffinity Technologies, Inc. today announced David Elzi, Ph.D., has been named Vice President of Product Development to accelerate the development of new diagnostics based on the proprietary technology platform behind CyPath® Lung, the Company’s commercial test for the detection of early-stage lung cancer.

bioAffinity Technologies, Inc. reported accelerating growth of 375% in CyPath® Lung tests ordered and processed over the past three months as compared to the previous three months.

bioAffinity Technologies, Inc., a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, provides a summary of recent Company news.

Here is a summary of the latest news about bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease.

bioAffinity Technologies, Inc. today announced the expansion of its partnership with the American Cancer Society (ACS) to raise funding for ACS’ Lung Quality Improvement (QI) initiative to increase the rate of lung cancer screening.

bioAffinity Technologies, Inc. announced it has closed a securities purchase agreement with institutional investors for the purchase and sale of 1,600,000 shares of common stock in a registered direct offering and common warrants to purchase up to 1,600,000 shares of common stock in a concurrent private placement at a combined purchase price of $1.5625 per common share.